… vulnerable breast cancer subtype to proteasome inhibition … sensitivity to the proteasome
inhibitors bortezomib, carfilzomib, … Differential expression between breast cancer and normal …

… proteasome inhibitor in DLBCL cell lines. Bortezomib and MG132 were used as proteasome
inhibitors… myelodysplastic symdrome, non-small cell lung cancer and breast cancer (32–36). …

… the feasibility of creating a proteasome inhibitor resistant myeloma cell lines by using clinically
… De-differentiated myeloma cells express B-cell markers, and it was recently reported that …

… This remained in effect also when bortezomib was used … We performed a differential
mRNA-level analysis between … increases the effect of the proteasome inhibition in cancer cells, we …

… Here, we show that ETC suppression promotes resistance to proteasome inhibitors (PIs).
Interrogation of ETC-suppressed MM reveals integrated stress response–dependent …

… Multiple myeloma (MM) is a cancer of plasma cells in the bone marrow … Bortezomib (BTZ),
a common treatment for MM, is a proteasome inhibitor that induces apoptosis in MM cells. …

… –approved proteasomal inhibitor bortezomib (BTZ) has … its dependence on proteasome
inhibition has been conclusively … its reliance on proteasome inhibition for these actions in vivo …

… , MG-341, PS-341), a potent 26S proteasome inhibitor, was the first of its kind to be approved
… -150 cells are poorly differentiated, it is possible that the apoptotic effect of Bortezomib may …

… proteasome inhibitor approved by the US FDA for the treatment of multiple myeloma (MM)
patients was bortezomib… Differential expression was determined by applying the linear models …

… proteasome inhibitors have been approved by the FDA for the treatment of multiple myeloma:
Bortezomib (Velcade, … Bortezomib was the first proteasome inhibitor to be approved by the …